MK lambasts delays in human experimentation rules

Tirosh criticizes Health Ministry for failure to speed up bill in Knesset committee; clinical trial requests are on the rise.

June 28, 2012 01:19
2 minute read.
Doctor bedside [illustrative photo]

Doctor bedside. (photo credit: Thinkstock/Imagebank)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Knesset Science and Technology Committee chairwoman MK Ronit Tirosh lambasted the Health Ministry on Wednesday for failing to speed up the preparation of a bill for the regulation of medical experimentation on humans, which has been waiting in the wings for a long period.

“It cannot be that modernization influences our lives so fast, while legislation is delayed and in the end will be irrelevant,” the MK said.

Be the first to know - Join our Facebook page.

The committee had heard details of the 2011 report on human experimentation showing that the number of requests for clinical trials has been increasing. Not only are patients participating in such trials, but tissues removed from patients undergo testing.

“The committee approves clinical trials after a stringent ethical examination,” the committee was told. Tirosh warned that much care must be taken regarding cloning in humans.

Prof. Zvi Borochovich, chairman of the Supreme Committee for Human Medical Experimentation, said: “Israel is at the forefront of work in the field of stem cells. The Helsinki Committee on Human Medical Experimentation changes from time to time and expands the rules, and everything is done according to the basic principles of human dignity and professional ethics. The studies have to pass many approvals after that it is ascertained that the study can in fact be carried out and that it could bring real benefits.”

The report noted that a draft for requesting the establishment of tissue samples for genetic research has already been prepared. Using existing technologies, nerve cells and tissues can be developed from a small sample of skin, saliva and even from a blood sample. These cells could be transplanted without rejection into the patient’s body to treat disease, it added.

“One must be careful and make sure that the patients in the trial understand the implications of the research into his tissue and [that] he agrees to be informed about certain diseases or other things of which he was unaware,” Borochovich added.

Tirosh congratulated the Supreme Committee on its work and said there is a rise in the number of applications for clinical trials. “This is all due to technological advances and researchers who want to improve medicine and knowledge. I view positively the insistence of the committee to be careful about genetic experimentation and cloning,” she said.

There is a need to simplify the consent letter that is signed by those involved in clinical studies so it will be written in simple and clear language, Tirosh concluded.

No response was obtained from the Health Ministry on Tirosh’s complaints.

Related Content

August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice